Sanofi’s Chronic Lung Disease Drug Gets EU Regulator Backing
(Bloomberg) -- Sanofi's Dupixent is close to being approved in Europe for use in helping patients with a chronic lung disorder, opening up another avenue of growth for the blockbuster drug.
The European Medicines Agency's Committee for Medicinal Products for Human Use said the shot could be used as an add-on treatment for chronic obstructive pulmonary disease patients with high levels of some white blood cells, according to a company statement Friday. The European Commission is expected to decide on the application in the coming months, it added.
If approved, Dupixent will be the first-ever targeted therapy for COPD in the EU. It will also be the first new treatment approach for this life-threatening inflammatory lung disease, which causes obstructed airflow from the lungs, in more than a decade, the company said.
The US Food and Drug Administration is also reviewing the drug for COPD and could decide by Sept. 27, Sanofi said. Regulators in China are also considering the matter.
Shares of Sanofi were little changed in early trading.
Read More: Sanofi's Dupixent Shows Strong Efficacy in Second Lung Trial
Dupixent, developed with Regeneron Pharmaceuticals Inc., is already one of the industry's top-performing medicines. It's currently prescribed for ailments ranging from asthma to some skin conditions. Sanofi recorded €10.7 billion ($11.6 billion) in sales from Dupixent last year, with demand still growing fast around the world.

The recommendation is a step forward for Sanofi Chief Executive Officer Paul Hudson, who is looking to transform the French drugmaker into a global powerhouse at developing next-generation therapies. Hudson surprised investors in October with a plan to increase drug-development spending, a decision that meant abandoning some older profit targets for now in hopes of creating more growth later this decade. The company is pushing a dozen potential top-selling medicines through costly clinical trials.
Read More: Sanofi CEO Shocks Investors With R&D Spending, Few Details
Two successful late-stage studies of Dupixent in people with COPD surprised many industry analysts, who had previously seen new therapies fail to help the condition, including AstraZeneca Plc's Fasenra and GSK Plc's Nucala.
(Updates to add shares in fifth paragraph)
More stories like this are available on bloomberg.com
©2024 Bloomberg L.P.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.